Baseline therapies of patients with rheumatic diseases
| Treatment | n (%) |
| Glucocorticoids | 91 (40.1) |
| Dose*, m±SD when taken | 9.9±11.5 |
| >10 mg/day prednisone equivalent | 15 (6.6) |
| csDMARD | 129 (56.6) |
| Methotrexate | 64 (28.1) |
| Antimalarial drugs | 28 (12.4) |
| Leflunomide | 20 (8.9) |
| Sulfasalazine | 17 (7.5) |
| Other immunosuppressants | 28 (12.3) |
| Mofetil mycophenolate | 12 (5.3) |
| Azathioprine | 7 (3.1) |
| Cyclophosphamide | 2 (0.8) |
| Calcineurin inhibitors | 7 (3.1) |
| ts/bDMARD | 53 (23.2) |
| TNF-α antagonists | 35 (15.4) |
| Rituximab | 5 (2.2) |
| IL-17/IL-23 antagonists | 4 (1.8) |
| Abatacept | 3 (1.3) |
| Tocilizumab | 2 (0.8) |
| Sarilumab | 1 (0.4) |
| Tofacitinib | 3 (1.3) |
*In mg/day of prednisone equivalents.
csDMARD, conventional synthetic disease-modifying antirheumatic drug; IL, interleukin; TNF, tumour necrosis factor; ts/bDMARD, targeted synthetic or biological disease-modifying antirheumatic drug.